



PRESS RELEASE

Indoco Q4 revenues grew 26 % YoY

Mumbai, May 7, 2026 : During the fourth quarter of FY 2025-26, revenues of Indoco Remedies are at ₹ 4,291 mn, as against ₹ 3,411 mn, same quarter last year. EBIDTA to net sales for the quarter is 14.7 % at ₹ 630 mn, compared to 1.0 % at ₹ 35 mn, same quarter last year.

For the year, revenues are at ₹ 16,335 mn, as against ₹ 14,948 mn, same period last year. EBIDTA to net sales for the period is 9.6 % at ₹ 1,572 mn, compared to 8.6 % at ₹ 1,280 mn, same period last year.

Commenting on the results, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "Revenue growth for the quarter and year was mainly driven by a good performance in the International Formulations Business, supported by a steady growth in the API & Services Businesses."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Otorex, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69 etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:



Mr. Anuj Sonpal
Valorem Advisors

Tel: +91-22-4903-9500

Email:

indoco@valoremadvisors.com/corpcom@indoco.com